DRKS00024085招募中3 期
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNS
IVERSITÄTSKLINIKUM FREIBURG; Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation0 个研究点目标入组 260 人开始时间: 2023年3月29日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 65 Years 至 one（—）
- 性别
- All
入选标准
- •1. Immunocompetent patients with newly-diagnosed primary DLBCL of the central nervous system.
- •2. Age > 70 years or age 65-70 years if not eligible for more intensive treatment (e.g. OptiMATe trial).
- •3. Histologically or cytologically assessed diagnosis of B-cell lymphoma by local pathologist.
- •4. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.
- •5. Disease exclusively located in the CNS.
- •6. At least 1 measurable lesion.
- •7. ECOG-Performance Status =2.
- •8. Patients possibly eligible for HCT-ASCT as judged by the treating physician.
- •9. Written informed consent obtained according to international guidelines and local laws by patient or authorized legal representative in case patient is temporarily legally not competent due to his or her disease.
- •Additional randomization criteria:
- •1. Patients eligible for HCT-ASCT defined by the EBL score (at most 1 of the 3 following conditions may apply: ECOG PS > 1, Barthel Index of ADL < 20 and Lachs geriatric screening > 3), improvement of PS after pre-phase treatment or clinical judgement by the treating physician after discussion with the study expert team.
- •2. No evidence of disease progression after pre-phase treatment.
排除标准
- •1. Congenital or acquired immunodeficiency including HIV infection and previous organ transplantation.
- •2. Systemic lymphoma manifestation (outside the CNS).
- •3. Primary vitreoretinal lymphoma or primary leptomeningeal lymphoma without manifestation in the brain parenchyma or spinal cord.
- •4. Previous or concurrent malignancies with the exception of surgically cured carcinoma in situ or other kinds of cancer without evidence of disease for at least 5 years.
- •5. Previous systemic Non-Hodgkin lymphoma at any time.
- •6. Inadequate renal function (creatinine clearance <60 ml/min).
- •7. Inadequate bone marrow, cardiac, pulmonary or hepatic function according to investigator´s decision.
- •8. Active hepatitis B or C disease.
- •9. Concurrent treatment with other experimental drugs or participation in an interventional clinical trial with administration of study medication within the last 30 days before the start of this study.
- •10. Clinically relevant third space fluid accumulation according to the investigator’s discretion.
- •11. Hypersensitivity to study treatment or any component of the formulation.
- •12. Taking any medications likely to cause interactions with the study medication.
- •13. Known or persistent abuse of medication, drugs or alcohol.
- •14. Active COVID-19-infection or non-compliance with the prevailing hygiene measures regarding the COVID-19 pandemic.
- •15. Patients without legal capacity and who are unable to understand the nature, significance and consequences of the study and without designated legal representative.
- •16. Previous participation in this trial.
- •17. Persons who are in a relationship of dependency/employment to the sponsor and/ or investigator.
- •18. Any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
- •19. Fertile patients refusing to use safe contraceptive methods during the study.
研究者
相似试验
招募中
1 期
Age-adapted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy and maintenance therapy in fit elderly patients* with initial diagnosis of primary cerebral lymphoma.EUCTR2020-001181-10-ATMedical Center - University of Freiburg310
进行中（未招募）
1 期
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNSPrimary diffuse large B-cell lymphoma of the central nervous system(PCNSL) is a rare lymphoma affecting only the central nervous systemcompartment. PCNSL patients are typically 60 years or older and havepoor prognoses. Considering the poor prognosis of this patientpopulation, this randomised phase III trial proposal is of great clinicalimportance to provide patients optimal treatment.CTIS2024-512320-11-00Medical Center - University Of Freiburg248
已完成
2 期
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patientsC85.1B-cell lymphoma, unspecifiedDRKS00011932niversitätsklinikum FreiburgMedizinische Klinik IHämatologie, Onkologie und Stammzelltransplantation53
进行中（未招募）
1 期
The principal objective of the study is to investigate tolerability of highdosechemotherapy and autologous stem cell transplant in elderly patientsolder than 65 years with newly-diagnosed or relapsed primary lymphomasof the central nervous system.Primary central nervous system lymphoma (PCNSL) is an aggressiveNon-Hodgkin Lymphoma (NHL) mostly of B-cell origin, which exclusivelyinvades the central nervous system compartment. It accounts for 3% to4% of all primary brain tumours and 4% to 6% of extra-nodallymphomas. The incidence of PCNSL in immunocompetent patients hasbeen steadily increasing over the last 30 years. Patients older than 60years account for more than 50% of all PCNSL cases.EUCTR2016-001628-72-DEMedical Center - University of Freiburg51
暂停
1 期
High-dose chemotherapy with transplantation of gene-modified haematopoietic stem cells for HIV-positive patients with malignant diseases indicating an HSCTB21Human immunodeficiency virus [HIV] disease resulting in malignant neoplasmsDRKS00000109Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation, Onkologisches Zentrum, Universitätsklinikum Hamburg-Eppendorf10